FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE and WRONG TECHNIQUE IN DEVICE USAGE PROCESS

Overview

WRONG TECHNIQUE IN DEVICE USAGE PROCESS is the #4 most commonly reported adverse reaction for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 2,925 FDA adverse event reports linking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to WRONG TECHNIQUE IN DEVICE USAGE PROCESS. This represents approximately 4.2% of all 70,190 adverse event reports for this drug.

Patients taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience wrong technique in device usage process should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

WRONG TECHNIQUE IN DEVICE USAGE PROCESS is moderately reported among FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE users, representing a notable but not dominant share of adverse events.

Other Side Effects of FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

In addition to wrong technique in device usage process, the following adverse reactions have been reported for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:

• DYSPNOEA — 5,246 reports
• DRUG INEFFECTIVE — 3,162 reports
• PRODUCT DOSE OMISSION ISSUE — 2,933 reports
• PRODUCT COMPLAINT — 2,598 reports
• COUGH — 2,510 reports
• DEATH — 2,244 reports
• PNEUMONIA — 1,862 reports
• ASTHMA — 1,558 reports
• CHRONIC OBSTRUCTIVE PULMONARY DISEASE — 1,444 reports
• FATIGUE — 1,210 reports

Other Drugs Associated with WRONG TECHNIQUE IN DEVICE USAGE PROCESS

The following drugs have also been linked to wrong technique in device usage process in FDA adverse event reports:

Does FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE cause WRONG TECHNIQUE IN DEVICE USAGE PROCESS?

WRONG TECHNIQUE IN DEVICE USAGE PROCESS has been reported as an adverse event in 2,925 FDA reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is WRONG TECHNIQUE IN DEVICE USAGE PROCESS with FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

WRONG TECHNIQUE IN DEVICE USAGE PROCESS accounts for approximately 4.2% of all adverse event reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.

What should I do if I experience WRONG TECHNIQUE IN DEVICE USAGE PROCESS while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

If you experience wrong technique in device usage process while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages